SMAD6抗体

+ +

•  

   

     Western blot analysis using SMAD6 mouse mAb against A431 (1), A431 (2), Hela (3) and Jurkat (4) cell lysate.    

  
  

SMAD6 antibody is a key tool for studying the SMAD6 protein, a member of the SMAD family that regulates transforming growth factor-beta (TGF-β) and bone morphogenetic protein (BMP) signaling pathways. SMAD6 acts primarily as an inhibitory SMAD (I-SMAD), functioning as a negative regulator of BMP signaling by competing with receptor-activated SMADs (R-SMADs, e.g., SMAD1/5/8) for receptor binding or promoting their dephosphorylation. It also modulates TGF-β signaling by interacting with SMAD4 or recruiting ubiquitin ligases to target receptors for degradation.

SMAD6 plays critical roles in embryonic development, cell differentiation, apoptosis, and immune regulation. Dysregulation of SMAD6 is linked to cardiovascular diseases, cancer, and skeletal disorders. For instance, SMAD6 mutations are associated with congenital heart defects, while its overexpression or underexpression has been observed in certain tumors, influencing metastasis and therapeutic resistance.

SMAD6 antibodies are widely used in research to detect protein expression, localization, and interactions via techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and co-immunoprecipitation (Co-IP). These antibodies are essential for elucidating SMAD6's role in signaling crosstalk, developmental biology, and disease mechanisms. Validated antibodies specifically target epitopes in the N-terminal or C-terminal regions of SMAD6. with monoclonal and polyclonal variants available. Researchers rely on these antibodies to explore SMAD6's context-dependent functions and its potential as a therapeutic target in pathological conditions.